Australian urologists are now using Orthocell’s flagship nerve repair product Remplir during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications caused ...
Australian urologists are now using Orthocell’s flagship nerve repair product Remplir during prostate cancer surgery in a promising new application. Perth-based regenerative medicine company Orthocell ...
PERTH, Australia, Sept. 16, 2025 /PRNewswire/ -- Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce its flagship nerve repair device, ...
More good news has come out of this growing company. Orthocell Ltd shares climbed 10% to $1.21 following the announcement of a new application for its nerve repair device, Remplir, in prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback